Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

GlobeNewswire February 6, 2023

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX(TM) (Ketamine) for the Treatment of Rett Syndrome

GlobeNewswire February 2, 2023

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX(TM) (Ketamine) in Parkinson's Disease

GlobeNewswire February 1, 2023

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

GlobeNewswire January 18, 2023

PharmaTher Holdings Provides Update for KETARX(TM) (Racemic Ketamine) Development Programs and Expected Milestones for 2023

GlobeNewswire January 11, 2023

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

GlobeNewswire December 15, 2022

PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease at Neuroscience 2022 by the Society for Neuroscience

GlobeNewswire November 14, 2022

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

GlobeNewswire November 1, 2022

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson's Disease

GlobeNewswire October 5, 2022

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

GlobeNewswire September 29, 2022

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson's Disease at the MDS International Congress of Parkinson's Disease and Movement Disorders®

GlobeNewswire September 16, 2022

PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX(TM) Ketamine Patch

GlobeNewswire September 7, 2022

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson's Disease and Motor Disorders

GlobeNewswire July 13, 2022

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

GlobeNewswire June 29, 2022

PharmaTher (CSE:PHRM) announces positive results from KETABET study

John Ballem  June 7, 2022

PharmaTher Announces Positive Results from Study of KETABET(TM) for Depression

GlobeNewswire June 7, 2022

PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

GlobeNewswire May 25, 2022

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

GlobeNewswire May 5, 2022

PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

GlobeNewswire April 25, 2022

PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

GlobeNewswire April 12, 2022